相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combinatorial inhibition of Plk1 and PKCβ in cancer cells with different p53 status
Lisa Lange et al.
ONCOTARGET (2014)
Discovery of TAK-960: An orally available small molecule inhibitor of polo-like kinase 1 (PLK1)
Zhe Nie et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens
Yuichi Hikichi et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype
Alan L. Ho et al.
PLOS ONE (2012)
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
Ingrid E. Wertz et al.
NATURE (2011)
An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors
Ralf-Dieter Hofheinz et al.
CLINICAL CANCER RESEARCH (2010)
Mcl-1; the molecular regulation of protein function
Luke W. Thomas et al.
FEBS LETTERS (2010)
Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours
Subbaya Subramanian et al.
JOURNAL OF PATHOLOGY (2010)
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy
Klaus Strebhardt
NATURE REVIEWS DRUG DISCOVERY (2010)
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Ji Luo et al.
CELL (2009)
The Topoisomerase I Poison CPT-11 Enhances the Effect of the Aurora B Kinase Inhibitor AZD1152 both In vitro and In vivo
Jayasree S. Nair et al.
CLINICAL CANCER RESEARCH (2009)
A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53
Surojit Sur et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Phase I Study of ON 01910.Na, a Novel Modulator of the Polo-Like Kinase 1 Pathway, in Adult Patients With Solid Tumors
Antonio Jimeno et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The BCL-2 protein family: opposing activities that mediate cell death
Richard J. Youle et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma
Samuel Singer et al.
CANCER RESEARCH (2007)
The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1
Peter Lenart et al.
CURRENT BIOLOGY (2007)
BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo
Martin Steegmaier et al.
CURRENT BIOLOGY (2007)
Opinion - Targeting polo-like kinase 1 for cancer therapy
K Strebhardt et al.
NATURE REVIEWS CANCER (2006)
Normal cells, but not cancer cells, survive severe Plk1 depletion
XQ Liu et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis
Q Zhong et al.
CELL (2005)
FoxM1 is required for execution of the mitotic programme and chromosome stability
J Laoukili et al.
NATURE CELL BIOLOGY (2005)
Polo-like kinases and oncogenesis
F Eckerdt et al.
ONCOGENE (2005)
Polo-like kinases (Plks) and cancer
N Takai et al.
ONCOGENE (2005)
Tumor regression by combination antisense therapy against Plk1 and Bcl-2
R Elez et al.
ONCOGENE (2003)
The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore
CS Stevenson et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease
L Kneisel et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2002)
Prognostic value of pololike kinase expression in melanomas
K Strebhardt et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
分享论文
